Research records indexed for Cagrilintide
This page carries 12 of the 103 records that the literature query returned for Cagrilintide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 91 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Cagrilintide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance pmid:42260119 | 2026 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice". subject headings: Neurons; Vagus Nerve; Prolactin-Releasing Hormone; Species Specificity; Energy Metabolism. |
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study pmid:42251859 | 2026 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Blood Glucose; Drug Combinations; Hypoglycemic Agents; Glucagon-Like Peptides. |
| Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study pmid:42251856 | 2026 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Insulin; Blood Glucose; Hypoglycemic Agents; Drug Therapy, Combination. |
| Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression pmid:41834765 | 2026 | Meta-Analysis, Comparative Study | other | Not stated | Indexed as meta-analysis, comparative study. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Blood Glucose; Anti-Obesity Agents; Glucagon-Like Peptides. |
| Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study pmid:42251860 | 2026 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Blood Glucose; Hypoglycemic Agents; Exercise; Drug Administration Schedule. |
| Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials pmid:42207966 | 2026 | Comparative Study, research-article | other | Not stated | Indexed as comparative study, research-article. study model from MeSH "Humans" with no interventional publication type. subject headings: Obesity; Weight Loss; Gastric Inhibitory Polypeptide; Anti-Obesity Agents; Overweight. |
| Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide pmid:42228334 | 2026 | research-article, Multicenter Study | human trial | Not stated | Indexed as research-article, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase i". subject headings: Liver Diseases; Hypoglycemic Agents; Injections, Subcutaneous; Area Under Curve; Renal Insufficiency. |
| Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial pmid:42009015 | 2026 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Drug Therapy, Combination; Japan. |
| Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors pmid:40847076 | 2026 | Journal Article | other | Not stated | Indexed as journal article. study model from MeSH "Animals" with no rodent species heading. subject headings: Receptors, Calcitonin; Cryoelectron Microscopy; Islet Amyloid Polypeptide; Receptors, Islet Amyloid Polypeptide; Amylin Receptor Agonists. |
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity pmid:40544433 | 2025 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Hypertension; Obesity; Weight Loss; Anti-Obesity Agents; Drug Combinations. |
| Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes pmid:40544432 | 2025 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Hypoglycemia; Obesity; Weight Loss; Blood Glucose. |
| Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 pmid:40609154 | 2025 | research-article | rodent | Not stated | Indexed as research-article. study model from MeSH "Mice, Knockout". subject headings: Brain; Mice, Knockout; Obesity; Body Weight; Calcitonin. |
Where this page sits
Compound page: Cagrilintide. Class: Amylin and amylin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 171397054, Cagrilintide. PubChem, National Library of Medicine (2026). pubchem:171397054
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cagrilintide
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
- AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. The Journal of pharmacology and experimental therapeutics (2021). pmid:33727283
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022). pmid:36242844
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) (2021). pmid:34798060
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (London, England) (2021). pmid:33894838
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England) (2023). pmid:37364590
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine (2025). pmid:40544433
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine (2025). pmid:40544432
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.